Results from a randomized, double-blind, placebo-controlled, exploratory, multicenter study of GBR 830 in adult patients with moderate-to-severe atopic dermatitis - 03/08/18
Doi : 10.1016/j.jaad.2018.05.976
Il testo completo di questo articolo è disponibile in PDF.
Emma Guttman-Yassky, MD, PhD, Icahn School of Medicine at Mount Sinai; Ana B. Pavel, PhD, Icahn School of Medicine at Mount Sinai; Yeriel Estrada, BS, Icahn School of Medicine at Mount Sinai; Ning Zhang, MD, Icahn School of Medicine at Mount Sinai; Xiangyu Peng, MS, Icahn School of Medicine at Mount Sinai; Hui Xu, MS, Icahn School of Medicine at Mount Sinai; Huei-Chi Wen, MD, PhD, Icahn School of Medicine at Mount Sinai; Hui Fang, PhD, Glenmark Pharmaceuticals, USA; Yacine Salhi, PhD, Glenmark Pharmaceuticals, USA
Il testo completo di questo articolo è disponibile in PDF.| Commercial support: Glenmark Pharmaceuticals, Inc., USA, Mahwah, New Jersey. Editorial assistance provided by Prescott Medical Communications Group, Chicago, Illinois, and funded by Glenmark Pharmaceuticals. |
© 2018
Pubblicato da Elsevier Masson SAS.
Vol 79 - N° 3S1
P. AB245 - settembre 2018 Ritorno al numero
Articolo precedente
- Response to secukinumab on psoriasis treatment in moderate-severe plaques. Response analysis according to previous treatments
- Retiform purpuric plaques: A classic sign of levamisole-induced vasculitis
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?